Amicus Therapeutics, Inc. (FOLD) Shares Bought by TIAA CREF Investment Management LLC

TIAA CREF Investment Management LLC raised its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 12.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 487,751 shares of the biopharmaceutical company’s stock after acquiring an additional 52,136 shares during the quarter. TIAA CREF Investment Management LLC owned approximately 0.34% of Amicus Therapeutics worth $4,912,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Teachers Advisors LLC increased its holdings in shares of Amicus Therapeutics by 3.2% in the second quarter. Teachers Advisors LLC now owns 261,545 shares of the biopharmaceutical company’s stock valued at $2,634,000 after purchasing an additional 8,046 shares during the last quarter. Alliancebernstein L.P. increased its stake in Amicus Therapeutics by 16.3% during the second quarter. Alliancebernstein L.P. now owns 205,836 shares of the biopharmaceutical company’s stock worth $2,073,000 after acquiring an additional 28,800 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in Amicus Therapeutics by 3,672.2% during the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock worth $685,000 after acquiring an additional 66,209 shares during the last quarter. Legal & General Group Plc increased its stake in Amicus Therapeutics by 1.6% during the second quarter. Legal & General Group Plc now owns 55,411 shares of the biopharmaceutical company’s stock worth $558,000 after acquiring an additional 852 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in Amicus Therapeutics during the second quarter worth $1,057,000.



Several research analysts have recently commented on the company. BidaskClub lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Chardan Capital raised their price target on Amicus Therapeutics from $12.50 to $17.50 and gave the stock a “buy” rating in a research report on Thursday, August 10th. JPMorgan Chase & Co. restated an “overweight” rating and set a $15.00 price target (up from $13.00) on shares of Amicus Therapeutics in a research report on Wednesday, August 9th. Cowen and Company reiterated a “buy” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a report on Monday, August 14th. Finally, Robert W. Baird lifted their target price on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, July 12th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $17.81.

Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at 13.45 on Friday. The firm’s market capitalization is $2.21 billion. Amicus Therapeutics, Inc. has a 1-year low of $4.41 and a 1-year high of $16.60. The firm has a 50-day moving average price of $14.35 and a 200-day moving average price of $11.26.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million during the quarter, compared to the consensus estimate of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same period in the previous year, the firm posted ($0.40) earnings per share. On average, analysts forecast that Amicus Therapeutics, Inc. will post ($1.32) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) Shares Bought by TIAA CREF Investment Management LLC” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/10/27/tiaa-cref-investment-management-llc-buys-52136-shares-of-amicus-therapeutics-inc-fold.html.

In other news, CEO John F. Crowley sold 449,295 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $14.33, for a total value of $6,438,397.35. Following the completion of the transaction, the chief executive officer now owns 380,723 shares in the company, valued at $5,455,760.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO William D. Baird III sold 40,000 shares of the stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $14.25, for a total transaction of $570,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 628,224 shares of company stock valued at $9,024,003. 3.40% of the stock is currently owned by insiders.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply